Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936

COSMO PHARMACEUTICALS N.V.

(COPN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Cosmo Pharmaceuticals: New exclusive Distribution Agreement for Eleview with Medtronic in the US, China and South America and further Collaboration Agreement to strengthen Cooperation in the Artificial Intelligence field

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/08/2019 | 01:05am EDT

Cosmo Pharmaceuticals: New exclusive Distribution Agreement for Eleview with Medtronic in the US, China and South America and further Collaboration Agreement to strengthen Cooperation in the Artificial Intelligence field

Dublin - May 8, 2019 - Cosmo Pharmaceuticals NV (SIX: COPN) announced today that it has entered into a new exclusive supply and distribution agreement for Eleview with Medtronic for the US, China and South America, having in the meantime terminated by mutual consent the co-marketing agreement with Olympus.

Further, Cosmo announced that it has entered into a Collaboration Agreement with Medtronic to start a research collaboration in Artificial Intelligence in GI and explore various technological solutions and related business opportunities.

"Thanks to the highly recognized expertise in GI and a decade of hard work and investments in endoscopy, we are now able to consistently strengthen our cooperation with Medtronic, the biggest player in medical technology. The Eleview deal allows the franchise to expand with an unrivalled marketing firepower, while the collaboration deal opens up new exciting perspectives for Artificial Intelligence in GI and marks Cosmo as a significant player in one of the most cutting-edge fields. We are proud of these new opportunities" said Alessandro Della Chà, CEO of Cosmo.




Provider
Channel
Contact
EQS Group Ltd., Switzerland
switzerland.eqs.com


newsbox.ch
www.newsbox.ch


Provider/Channel related enquiries
cs.switzerland@eqs.com
+41 41 763 00 50
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COSMO PHARMACEUTICALS N.V.
07/30Cosmo Half-Year Report 2019
TE
07/05Cosmo Pharmaceuticals Posts GI Genius Video Demonstration at Image 2019 Confe..
TE
07/02COSMO PHARMACEUTICALS : announces Canadian Agency approval of Eleview for endosc..
AQ
07/01Cosmo Pharmaceuticals announces Canadian Agency approval of Eleview® for endo..
TE
06/24COSMO PHARMACEUTICALS : announces Publication of Review of Aemcolo as Treatment ..
AQ
06/21Cosmo Pharmaceuticals announces Publication of Review of Aemcolo™ as Tr..
TE
06/11COSMO PHARMACEUTICALS : N.V. - FDA accepts filing of NDA for Remimazolam
AQ
06/10FDA accepts filing of NDA for Remimazolam
TE
05/29COSMO PHARMACEUTICALS' : Shareholders approve all Agenda Items at Annual General..
AQ
05/28Cosmo Pharmaceuticals' Shareholders approve all Agenda Items at Annual Genera..
TE
More news
Financials (EUR)
Sales 2019 47,6 M
EBIT 2019 -22,9 M
Net income 2019 -32,9 M
Finance 2019 146 M
Yield 2019 -
P/E ratio 2019 -30,4x
P/E ratio 2020 -93,9x
EV / Sales2019 17,7x
EV / Sales2020 8,83x
Capitalization 985 M
Chart COSMO PHARMACEUTICALS N.V.
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 106,11  €
Last Close Price 67,38  €
Spread / Highest target 102%
Spread / Average Target 57,5%
Spread / Lowest Target 23,9%
EPS Revisions
Managers
NameTitle
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer
Luigi Moro Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
COSMO PHARMACEUTICALS N.V.-15.47%1 089
JOHNSON & JOHNSON1.29%350 587
ROCHE HOLDING AG19.25%248 542
MERCK AND COMPANY11.29%217 734
PFIZER-16.38%201 883
NOVARTIS16.20%198 243